Pacific Edge (ASX:PEB) Momentum Rank: 4 (As of Sep. 21, 2026) — 33% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PEB Pacific Edge Ltd ASX:PEB
44 GF Score
Price A$0.22
GF Value A$0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pacific Edge Momentum Rank?

Pacific Edge ASX:PEB 44 Momentum Rank is 4 as of Sep. 21, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates ASX:PEB with a GF Score™ of 44/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Pacific Edge has the Momentum Rank of 4.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pacific Edge Momentum Rank Related Terms

ASX:PEB vs TMO, DHR, NTRA: Momentum Rank Comparison

For the Diagnostics & Research subindustry, Pacific Edge's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Edge Momentum Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Pacific Edge's Momentum Rank falls into.


ASX:PEB
44GF Score
Pacific Edge Ltd ASX:PEB
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 4 mean?
Pacific Edge (ASX:PEB) has a Momentum Rank of 4 as of Sep. 21, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Pacific Edge and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Pacific Edge's Momentum Rank has ranged from 1.00 to 10.00.
Is Pacific Edge's Momentum Rank too high?
Pacific Edge's current Momentum Rank of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Pacific Edge has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Momentum Rank compare to TMO and DHR?
Pacific Edge's Momentum Rank of 4 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Pacific Edge's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Diagnostics & Research company?
A good Momentum Rank depends on the Medical Diagnostics & Research industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Pacific Edge and its competitors. Pacific Edge's current Momentum Rank is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.22 — trading 340% above its estimated fair value. The current Momentum Rank is 4, which is 33% above median its 10-year median of 3.00. Pacific Edge's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Momentum Rank is 4 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.22 is trading 340% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • Momentum Rank: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: A$0.05 vs. price of A$0.22 (340% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
44GF Score

Get the complete analysis for ASX:PEB

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.22
Price
A$0.05
GF Value